Apr 8, 2019

Acute Leukemias Update — Part 1: Our interview with Dr Levis highlights the following topics as well as cases from his practice:

• Molecular profiling in the diagnosis and treatment of acute myeloid leukemia (AML) (00:00)
• Management of AML with p53 mutations (03:13)
• Efficacy of hypomethylating agents with venetoclax in older patients with AML (06:41)
• Therapeutic options for patients with AML and FLT3 mutations (10:31)
• Monitoring and management of venetoclax-associated tumor lysis syndrome (13:06)
• Case: A 62-year-old woman who presents with fatigue and bleeding gums is diagnosed with AML with FLT3 and NPM1 mutations (16:08)
• Role of the FLT3 pathway in myeloid cell development and types of FLT3 mutations (17:10)
• Impact of FLT3 mutations on therapeutic decision-making (21:01)
• Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (23:48)
• BMT CTN 1506: A Phase III trial of gilteritinib as maintenance therapy after allogeneic transplant for patients with AML and FLT3-ITD mutations (25:20)
• Case: A 60-year-old man with AML and a FLT3-ITD mutation receives gilteritinib with standard 7 + 3 chemotherapy induction followed by allotransplant and maintenance gilteritinib on a clinical trial (27:20)
• Similarities and differences among midostaurin, quizartinib and gilteritinib (28:58)
• Case: A 63-year-old man with refractory AML and an IDH2 mutation receives enasidenib and develops differentiation syndrome (31:46)
• Biologic rationale for targeting IDH1/2 mutations and activity of ivosidenib or enasidenib in patients with relapsed/refractory AML (35:57)
• Efficacy and side effects of CPX-351 (liposomal cytarabine/daunorubicin) in patients with AML (40:46)
• Case: A 28-year-old obese man with acute lymphoblastic leukemia (ALL) and an MLL rearrangement develops hepatic toxicity after treatment with the Berlin-Frankfurt-Munster pediatric-inspired regimen containing L-asparaginase (43:01)
• Mechanism of action, activity and tolerability of blinatumomab for ALL (46:38)
• Neurologic side effects associated with blinatumomab (49:03)
• Use of blinatumomab for minimal residual disease-positive ALL (51:53)
• Optimal use of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive ALL (53:30)
• Case: A 41-year-old woman receives chimeric antigen receptor (CAR) T-cell therapy for relapsed ALL (58:37)
• Role of CAR T-cell therapy in the management of ALL (1:01:31)
• Use of the antibody-drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin for acute leukemias (1:07:42)
• Activity of gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL) (1:10:30)

Select publications